Caregen Co., Ltd. (KOSDAQ:214370)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 1.34T |
| Revenue (ttm) | 78.67B |
| Net Income (ttm) | 35.79B |
| Shares Out | 48.99M |
| EPS (ttm) | 728.00 |
| PE Ratio | 37.57 |
| Forward PE | 28.34 |
| Dividend | 880.00 (3.22%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 60,657 |
| Average Volume | 205,272 |
| Open | 26,800 |
| Previous Close | 26,800 |
| Day's Range | 26,650 - 27,450 |
| 52-Week Range | 14,850 - 35,400 |
| Beta | 0.17 |
| RSI | 42.63 |
| Earnings Date | Feb 5, 2025 |
About Caregen
Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira... [Read more]
Financial Performance
In 2023, Caregen's revenue was 79.21 billion, an increase of 14.63% compared to the previous year's 69.10 billion. Earnings were 39.93 billion, an increase of 46.44%.
Financial StatementsNews
Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen
Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...
Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion
Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...